Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim

Expert Review of Pharmacoeconomics & Outcomes Research
Simrun GrewalJosh J Carlson

Abstract

Biosimilars can directly reduce the cost of treating patients for whom a reference biologic is indicated by offering a highly similar, lower priced alternative. We examine factors related to biosimilar regulatory approval, uptake, pricing, and financing and the potential impact on drug expenditures in the U.S. We developed a framework to illustrate how key factors including regulatory policies, provider and patient perception, pricing, and payer policies impact biosimilar cost-savings. Further, we developed a budget impact cost model to estimate savings from filgrastim biosimilars under various scenarios. The model uses publicly available data on disease incidence, treatment patterns, market share, and drug prices to estimate the cost-savings over a 5-year time horizon. We estimate five-year cost savings of $256 million, of which 18% ($47 million) are from reduced patient out-of-pocket costs, 34% ($86 million) are savings to commercial payers, and 48% ($123 million) are savings for Medicare. Additional scenarios demonstrate the impact of uncertain factors, including price, uptake, and financing policies. A variety or interrelated factors influence the development, uptake, and cost-savings for Biosimilars use in the U.S. The fil...Continue Reading

References

Sep 18, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H MellstedtH Ludwig
Mar 29, 2011·MAbs·Mark McCamish, Gillian Woollett
Oct 19, 2011·Journal of the National Comprehensive Cancer Network : JNCCN·Andrew D ZelenetzJames M Hoffman
Jan 22, 2014·Nature Reviews. Drug Discovery·Henry GrabowskiMaria Salgado
Mar 7, 2014·Journal of Crohn's & Colitis·Hans C Ebbers
Nov 5, 2016·Annual Review of Medicine·Leah A ChristlSteven Kozlowski
Apr 21, 2017·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Alice Yuen-Ting WongAlbert Wai-Kit Chan
Feb 15, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gary H LymanRichard L Schilsky

❮ Previous
Next ❯

Citations

Dec 12, 2018·Journal of Oncology Practice·Douglas W Blayney
Feb 15, 2019·Expert Review of Pharmacoeconomics & Outcomes Research·Lajos HornyákImre Boncz
Sep 22, 2019·Drugs·Pier Luigi ZinzaniGiuseppe Curigliano
Jun 20, 2020·PharmacoEconomics Open·Melissa H Roberts, Gary T Ferguson
Jan 15, 2020·Pharmaceutical Medicine·Stanton R Mehr, Richard A Brook
Apr 29, 2021·Journal of Managed Care & Specialty Pharmacy·Jingjing Qian
Nov 3, 2021·Journal of Managed Care & Specialty Pharmacy·Jentora WhiteHima Patel

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Advances in Health Economics and Health Services Research
Jie Chen, John A Rizzo
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
D PutignanoE Menditto
The American Journal of Managed Care
Benjamin Yu
© 2022 Meta ULC. All rights reserved